Design, Synthesis, and Pharmacological Evaluation of 2-(2,5-Dimethyl-5,6,7,8-tetrahydroquinolin-8-yl)-N-aryl Propanamides as Novel Smoothened (Smo) Antagonists

Gang Liu, Ding Xue, Jun Yang, Juan Wang, Xiaohua Liu, Wenjing Huang, Jie Li, Ya Qiu Long, Wenfu Tan, Ao Zhang

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

A series of novel Smo antagonists were developed either by directly incorporating the basic skeleton of the natural product artemisinin or by first breaking artemisinin into structurally simpler and stable intermediates and then reconstructing into diversified heterocyclic derivatives, equipped with a Smo-targeting bullet. 2-(2,5-Dimethyl-5,6,7,8-tetrahydroquinolin-8-yl)-N-arylpropanamide 65 was identified as the most potent, with an IC50 value of 9.53 nM against the Hh signaling pathway. Complementary mechanism studies confirmed that 65 inhibits Hh signaling pathway by targeting Smo and shares the same binding site as that of the tool drug cyclopamine. Meanwhile, 65 has a good plasma exposure and an acceptable oral bioavailability. Dose-dependent antiproliferative effects were observed in ptch+/-;p53-/- medulloblastoma cells, and significant tumor growth inhibitions were achieved for 65 in the ptch+/-;p53-/- medulloblastoma allograft model.

Original languageEnglish (US)
Pages (from-to)11050-11068
Number of pages19
JournalJournal of Medicinal Chemistry
Volume59
Issue number24
DOIs
StatePublished - Dec 22 2016
Externally publishedYes

Fingerprint

Medulloblastoma
Pharmacology
Biological Products
Skeleton
Biological Availability
Inhibitory Concentration 50
Allografts
Binding Sites
Growth
Pharmaceutical Preparations
Neoplasms
artemisinine
5,6,7,8-tetrahydroquinoline
cyclopamine

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Design, Synthesis, and Pharmacological Evaluation of 2-(2,5-Dimethyl-5,6,7,8-tetrahydroquinolin-8-yl)-N-aryl Propanamides as Novel Smoothened (Smo) Antagonists. / Liu, Gang; Xue, Ding; Yang, Jun; Wang, Juan; Liu, Xiaohua; Huang, Wenjing; Li, Jie; Long, Ya Qiu; Tan, Wenfu; Zhang, Ao.

In: Journal of Medicinal Chemistry, Vol. 59, No. 24, 22.12.2016, p. 11050-11068.

Research output: Contribution to journalArticle

Liu, Gang ; Xue, Ding ; Yang, Jun ; Wang, Juan ; Liu, Xiaohua ; Huang, Wenjing ; Li, Jie ; Long, Ya Qiu ; Tan, Wenfu ; Zhang, Ao. / Design, Synthesis, and Pharmacological Evaluation of 2-(2,5-Dimethyl-5,6,7,8-tetrahydroquinolin-8-yl)-N-aryl Propanamides as Novel Smoothened (Smo) Antagonists. In: Journal of Medicinal Chemistry. 2016 ; Vol. 59, No. 24. pp. 11050-11068.
@article{1480eefdfe7e48618a6c4a1ea9db5716,
title = "Design, Synthesis, and Pharmacological Evaluation of 2-(2,5-Dimethyl-5,6,7,8-tetrahydroquinolin-8-yl)-N-aryl Propanamides as Novel Smoothened (Smo) Antagonists",
abstract = "A series of novel Smo antagonists were developed either by directly incorporating the basic skeleton of the natural product artemisinin or by first breaking artemisinin into structurally simpler and stable intermediates and then reconstructing into diversified heterocyclic derivatives, equipped with a Smo-targeting bullet. 2-(2,5-Dimethyl-5,6,7,8-tetrahydroquinolin-8-yl)-N-arylpropanamide 65 was identified as the most potent, with an IC50 value of 9.53 nM against the Hh signaling pathway. Complementary mechanism studies confirmed that 65 inhibits Hh signaling pathway by targeting Smo and shares the same binding site as that of the tool drug cyclopamine. Meanwhile, 65 has a good plasma exposure and an acceptable oral bioavailability. Dose-dependent antiproliferative effects were observed in ptch+/-;p53-/- medulloblastoma cells, and significant tumor growth inhibitions were achieved for 65 in the ptch+/-;p53-/- medulloblastoma allograft model.",
author = "Gang Liu and Ding Xue and Jun Yang and Juan Wang and Xiaohua Liu and Wenjing Huang and Jie Li and Long, {Ya Qiu} and Wenfu Tan and Ao Zhang",
year = "2016",
month = "12",
day = "22",
doi = "10.1021/acs.jmedchem.6b01247",
language = "English (US)",
volume = "59",
pages = "11050--11068",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "24",

}

TY - JOUR

T1 - Design, Synthesis, and Pharmacological Evaluation of 2-(2,5-Dimethyl-5,6,7,8-tetrahydroquinolin-8-yl)-N-aryl Propanamides as Novel Smoothened (Smo) Antagonists

AU - Liu, Gang

AU - Xue, Ding

AU - Yang, Jun

AU - Wang, Juan

AU - Liu, Xiaohua

AU - Huang, Wenjing

AU - Li, Jie

AU - Long, Ya Qiu

AU - Tan, Wenfu

AU - Zhang, Ao

PY - 2016/12/22

Y1 - 2016/12/22

N2 - A series of novel Smo antagonists were developed either by directly incorporating the basic skeleton of the natural product artemisinin or by first breaking artemisinin into structurally simpler and stable intermediates and then reconstructing into diversified heterocyclic derivatives, equipped with a Smo-targeting bullet. 2-(2,5-Dimethyl-5,6,7,8-tetrahydroquinolin-8-yl)-N-arylpropanamide 65 was identified as the most potent, with an IC50 value of 9.53 nM against the Hh signaling pathway. Complementary mechanism studies confirmed that 65 inhibits Hh signaling pathway by targeting Smo and shares the same binding site as that of the tool drug cyclopamine. Meanwhile, 65 has a good plasma exposure and an acceptable oral bioavailability. Dose-dependent antiproliferative effects were observed in ptch+/-;p53-/- medulloblastoma cells, and significant tumor growth inhibitions were achieved for 65 in the ptch+/-;p53-/- medulloblastoma allograft model.

AB - A series of novel Smo antagonists were developed either by directly incorporating the basic skeleton of the natural product artemisinin or by first breaking artemisinin into structurally simpler and stable intermediates and then reconstructing into diversified heterocyclic derivatives, equipped with a Smo-targeting bullet. 2-(2,5-Dimethyl-5,6,7,8-tetrahydroquinolin-8-yl)-N-arylpropanamide 65 was identified as the most potent, with an IC50 value of 9.53 nM against the Hh signaling pathway. Complementary mechanism studies confirmed that 65 inhibits Hh signaling pathway by targeting Smo and shares the same binding site as that of the tool drug cyclopamine. Meanwhile, 65 has a good plasma exposure and an acceptable oral bioavailability. Dose-dependent antiproliferative effects were observed in ptch+/-;p53-/- medulloblastoma cells, and significant tumor growth inhibitions were achieved for 65 in the ptch+/-;p53-/- medulloblastoma allograft model.

UR - http://www.scopus.com/inward/record.url?scp=85007271080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007271080&partnerID=8YFLogxK

U2 - 10.1021/acs.jmedchem.6b01247

DO - 10.1021/acs.jmedchem.6b01247

M3 - Article

VL - 59

SP - 11050

EP - 11068

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 24

ER -